Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
05/2003
05/02/2003EP1305309A1 Lactam inhibitors of factor xa which are useful for the treatment of thrombosis
05/02/2003EP1305306A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
05/02/2003EP1305304A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor
05/02/2003EP1305303A1 NOVEL FORM OF (R)- i N /i - 5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE
05/02/2003EP1305300A1 Novel, slow-acting betamimetics, a method for their production and their use as medicaments
05/02/2003EP1305295A1 Imidazole derivatives
05/02/2003EP1305294A2 Imidazolyl derivatives
05/02/2003EP1305293A1 Hexahydro-7-imino-1h-azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible nitric oxide synthase
05/02/2003EP1305288A1 Potassium channel inhibitors
05/02/2003EP1305285A1 N-substituted indoles useful in the treatment of diabetes
05/02/2003EP1305026A2 Barbituric acid analogs as therapeutic agents
05/02/2003EP1305024A1 Method for treating fibrotic diseases or other indications ic
05/02/2003EP1305023A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
05/02/2003EP1305020A2 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure
05/02/2003EP1305017A1 Methods and compositions for the prevention and treatment of syndrome x
05/02/2003EP1305013A1 Preparation with vascular protective and anti-oxidative effect and use thereof
05/02/2003EP1305007A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
05/02/2003EP1305006A2 Dispersions for formulating slightly or poorly soluble active ingredients
05/02/2003EP1221939A4 Ortho ester lipids
05/02/2003EP1196167A4 Method of reducing neuronal injury or apoptosis
05/02/2003EP1194186B1 CARDIOACTIVE COMPOSITION COMPRISING L-CARNITINE AND ITS DERIVATIVES AND i CRATAEGUS /i EXTRACTS
05/02/2003EP1185516B1 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
05/02/2003EP1140115B1 Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
05/02/2003EP1121351A4 Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes
05/02/2003EP1119351B1 Use of catechol derivatives as proteinase inhibitors
05/02/2003EP1070058B1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
05/02/2003EP1045846B1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
05/02/2003EP1025082B1 Novel vitamin d derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments
05/02/2003EP0988035B1 Caspases and apoptosis
05/02/2003EP0929578B1 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
05/02/2003EP0918761B1 Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
05/02/2003EP0910563B1 Integrin receptor antagonists
05/02/2003EP0901482B1 Benzofuran carboxamides and their therapeutic use
05/02/2003EP0797439B1 Use of pramipexole as a neuroprotective agent
05/02/2003EP0786988B1 Use of nk1 receptor antagonists for preparing cardio-regulatory drugs
05/02/2003EP0738150B1 Bicyclic fibrinogen antagonists
05/02/2003EP0706396B1 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and use
05/02/2003CA2411015A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/02/2003CA2411011A1 5-heteroatom-substituted pyrazoles
05/02/2003CA2411009A1 Heterocyclo-alkylsulfonyl pyrazoles
05/02/2003CA2410466A1 Hydrazinyl and nitrogen oxide pyrazoles
05/02/2003CA2410364A1 5-heterocyclo-pyrazoles
05/01/2003WO2003035855A1 Differentiation of whole bone marrow
05/01/2003WO2003035847A2 Il-13 mutein proteins, antibodies, compositions, methods and uses
05/01/2003WO2003035838A2 Stem cells that transform to beating cardiomyocytes
05/01/2003WO2003035835A2 Glycoprotein compositions
05/01/2003WO2003035687A1 Nogo receptor homologues and their use
05/01/2003WO2003035684A1 Ee3-protein family and corresponding dna sequences
05/01/2003WO2003035683A2 Surfactant protein-d and atherosclerosis
05/01/2003WO2003035679A2 Molecules
05/01/2003WO2003035678A2 Sperm factor sequences
05/01/2003WO2003035670A2 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
05/01/2003WO2003035666A2 Phosphorothioate-modified oligonucleotide as anti-restenosis agent
05/01/2003WO2003035659A1 Acarbose purification process
05/01/2003WO2003035654A1 Phosphonic acid compounds as inhibitors of serine proteases
05/01/2003WO2003035653A1 Pyridothienopyrimidine compound and salt thereof
05/01/2003WO2003035650A1 Entry inhibitor
05/01/2003WO2003035649A1 Imidazopyridine compounds as 5-ht4 receptor modulators
05/01/2003WO2003035646A2 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist
05/01/2003WO2003035644A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003WO2003035640A1 Pyrimidone compounds and pharmaceutical compositions containing the same
05/01/2003WO2003035639A1 Pyrimidine compound and medicinal composition thereof
05/01/2003WO2003035638A1 4-imidazolin-2-one compounds
05/01/2003WO2003035635A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003WO2003035627A1 Piperazine derivatives with ccr1 receptor antagonist activity
05/01/2003WO2003035626A2 Azole derivatives and pharmaceutical compositions containing them
05/01/2003WO2003035623A1 Method of resolving amlodipine racemate
05/01/2003WO2003035603A1 Acetic acid derivatives
05/01/2003WO2003035137A2 Method and apparatus for dispensing inhalator medicament
05/01/2003WO2003035135A1 Optimized dosing for drug coated stents
05/01/2003WO2003035110A1 Treating vascular disease by inhibiting toll-like receptor-4
05/01/2003WO2003035099A1 Biphasic mixtures of glp-1 and insulin
05/01/2003WO2003035085A1 Allium sativum bulb absolutes and therapeutic or cosmetic uses
05/01/2003WO2003035079A1 A combination product comprising melagatran and dexamethasone
05/01/2003WO2003035075A1 Inhibitors of human phosphatidyl-inositol 3-kinase delta
05/01/2003WO2003035069A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction
05/01/2003WO2003035065A1 Benzimidazoles and analogues and their use as protein kinases inhibitors
05/01/2003WO2003035064A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
05/01/2003WO2003035062A1 Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
05/01/2003WO2003035055A1 Mch antagonists for the treatment of obesity
05/01/2003WO2003035046A2 Salts formed of an at1-receptor antagonist and a cardiovascular agent
05/01/2003WO2003035039A1 Methods of treatment using a gastric retained losartan dosage
05/01/2003WO2003035008A2 Functionalized stilbene derivatives as improved vascular targeting agents
05/01/2003WO2003035005A2 Heteroindanes: a new class of potent cannabimimetic ligands
05/01/2003WO2003034995A2 Integrin targeting compounds
05/01/2003WO2003034987A2 Androgen receptor modulators and methods of use thereof
05/01/2003WO2003008412A3 Hetero-bicyclic crf antagonists
05/01/2003WO2003007840A3 Stent vascular intervention device and method
05/01/2003WO2003005970A3 Carvedilol polymorph
05/01/2003WO2003004040A3 Dietetic preparation with hypocholesterolemic activity
05/01/2003WO2003002109A8 Use of tyrosine kinase inhibitors for treating autoimmune diseases
05/01/2003WO2002102782A3 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE
05/01/2003WO2002100336A3 Tissue-specific endothelial membrane proteins
05/01/2003WO2002098444A3 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
05/01/2003WO2002090352A3 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
05/01/2003WO2002085293A3 Production of alpha-lipoic acid
05/01/2003WO2002083712A3 Transporters and ion channels
05/01/2003WO2002081520A3 Single chain dimeric polypeptides derived from the vegf family
05/01/2003WO2002076438A3 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
05/01/2003WO2002074806A3 New interferon beta-like molecules
1 ... 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 ... 1595